A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists by Hurley, M Yadira et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Diagnostic Pathology
Open Access Case Report
A transient benign lymph node-based proliferation of T-cells 
simulating non-Hodgkin lymphoma in a patient with psoriasis 
treated with tumor necrosis factor alpha and CD11a antagonists
M Yadira Hurley, Mary Noel George, Craig L Leonardi and John L Frater*
Address: Departments of Dermatology (Hurley, George, Leonardi) and Pathology (Frater), Saint Louis University School of Medicine, St Louis, 
MO, USA
Email: M Yadira Hurley - yadirahr@yahoo.com; Mary Noel George - georgemn@hotmail.com; 
Craig L Leonardi - craig.leonardi@centralderm.com; John L Frater* - jfrater@wustl.edu
* Corresponding author    
Abstract
Background: Therapeutic biologic agents are uncommonly associated with lymphoma.
Case presentation: We report a patient with psoriasis treated with the biologic agents
efalizumab (Raptiva®) and etanercept (Enbrel®), who developed painless lymphadenopathy with
peripheral lymphocytosis during treatment, simulating a non-Hodgkin lymphoma clinically and
pathologically. Lymphocytosis and lymphadenopathy spontaneously remitted following cessation of
etanercept therapy and have not recurred.
Conclusion: Distinction between clinically benign lymphoid proliferations related to antipsoriasis
therapy and malignant lymphoma avoids the unnecessary use of anti-lymphoma chemotherapy.
Background
In the epidermal milieu of psoriasis, activated CD4+
helper T-cells interact with CD8+ suppressor T-cells, den-
dritic cells, and keratinocytes, resulting in production of
TH1-associated cytokines, the most important of which is
tumor necrosis factor (TNF) [1]. In an effort to rationally
treat psoriasis, several biologic therapies have been engi-
neered. One of these is etanercept (Enbrel®), a dimeric
fusion protein that blocks the effects of TNFα [2]. Another
is efalizumab (Raptiva®), a humanized monoclonal anti-
body that binds to the CD11a subunit of lymphocyte
function-associated antigen-1 (LFA-1) to inhibit activa-
tion, trafficking to the dermis and epidermis, and reactiva-
tion of pathogenic T-cells. Use of biologics has been
associated with adverse effects such as infection and
autoantibody generation. There may also be a slight
increase in the risk of lymphoma, but the data is contro-
versial and may be confounded by the increased incidence
of lymphoma in the general psoriasis population [2].
Like many diseases, psoriasis is postulated to induce rela-
tive immunosuppression. The increased incidence of
infection and autoantibody generation suggests that fur-
ther aberrations of immune status may be engendered by
biologic therapy. This immunomodulation has been asso-
ciated with a spectrum of lymphoproliferative disorders,
some of which are clearly represent malignant lympho-
mas, others which are due to a dysregulated immune
response. The distinction between these two extremes has
important implications for selection of appropriate ther-
apy. We report a clinically benign proliferation of T-cells
simulating a non-Hodgkin lymphoma arising in a psoria-
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sis patient after beginning treated with efalizumab and
etanercept, discuss the pathologic features and choice of
treatment, and review the literature.
Case presentation
A 36 year-old white woman with an 11-year history of
psoriasis who after having maintained relatively good
control with class I topical steroids and calcipotriene oint-
ment flared to 30% total body surface area involvement.
She was unresponsive to a 9 month course of efalizumab
(Raptiva®) 1 mg/kg/wk including a 5 month overlap with
methotrexate at 5 mg/wk. She was then transitioned to
etanercept (Enbrel®), 50 mg subcutaneously biweekly:
efalizumab was overlapped 4 weeks to avoid psoriasis
worsening. Psoriasis worsening has been reported when
patients discontinue efalizumab, in particular patients
that that are partial or nonresponders. Over the course of
these overlap weeks she developed non-tender, bilateral
cervical lymphadenopathy. She denied other symptoms.
A complete blood count performed at this time revealed a
white blood cell count of 11.9 k/mcl, hemoglobin 14.6 g/
dL, and platelet count of 218.0 k/mcl., and a differential
count included 30.8% neutrophils, 62.2% lymphocytes,
and 7.0% monocytes. Circulating lymphocytes were small
and mature-appearing. A lymph node biopsy was per-
formed. Microscopic examination of the enlarged lymph
node revealed diffuse effacement of the normal nodal
architecture by an infiltrate composed of small lym-
phocytes, macrophages, and plasma cells. The capsule was
intact and thin and the nodal sinuses were obliterated.
The lymphocytes were a mix of CD4 positive T-helper and
CD8 positive T-suppressor cells. Although follicles were
not apparent in sections stained with hematoxylin and
eosin, immunohistochemistry revealed small clusters of
CD10 and BCL6 positive small lymphocytes, correspond-
ing to residual germinal centers. CD23 immunohisto-
chemistry showed the dendritic cell network to be
essentially obliterated (Figures 1 and 2). Plasma cells were
present individually and in variably sized clusters located
throughout the node. By immunohistochemistry, they
were composed of a polyclonal mixture of kappa and
lambda light chain positive cells. Flow cytometric analysis
of the peripheral blood revealed a lymphocytosis com-
posed of a mixture of CD4+ T-helper and CD8+ T-sup-
pressor cells. The patient was instructed to stop all
biologic agents. The lymphadenopathy resolved over the
following 2 months, and the patient remained without
adenopathy for 2 months. At that time etanercept was
restarted at 50 mg subcutaneously weekly with good con-
trol of her psoriasis and no recurrence of her adenopathy
for 23 months.
Discussion
We report a self-limited nodal-based clinically benign
proliferation of T-cells developing in a patient with pso-
riasis treated concurrently with the TNFα inhibitor etaner-
cept and the anti-CD11a antibody efalizumab. To avoid
the unnecessary use of anti-lymphoma chemotherapy, it
is important to recognize that these entities do not behave
in a malignant fashion. Our case is difficult to categorize
on the basis of the histopathologic findings alone. The
lymph node had several hallmarks of malignancy, includ-
ing diffuse effacement of the normal nodal architecture
and obliteration of the sinuses. Although a phenotypically
abnormal T-cell population was not identified by flow
cytometry or immunohistochemistry, this does not rule
out the possibility of a peripheral T-cell lymphoma, some
cases of which show normal immunophenotypes.
Although PCR-based T-cell receptor gene rearrangement
studies are sometimes employed in an effort to assess
clonality in cases of suspected T-cell lymphomas, the pres-
ence of a clonal result is not diagnostic of malignancy, and
may be seen in a variety of benign conditions. For this rea-
son, and because the symptoms ameliorated following
cessation of therapy, suggesting a benign condition, we
did not perform gene rearrangement studies. The identifi-
cation of other cell types besides lymphocytes in the infil-
trate also does not exclude a malignant lymphoma. In
fact, a heterogeneous background population is often
identified in lymph nodes involved by T-lineage lympho-
mas. The development of lymphadenopathy after com-
bining anti-TNF and anti-CD11a therapy and the prompt
resolution of symptoms after their discontinuation, fol-
lowed by lack of recurrence with using anti-TNF therapy
alone, suggests that these drugs caused or facilitated the
development of this process. Furthermore, the complete
resolution of symptoms without the use of chemotherapy
suggests that this lymphoproliferative disorder to clini-
cally similar to disorders occurring in other immunocom-
promised patient populations.
Lymphoproliferative disorders occurring in the immuno-
suppressed/immunocompromised population share
many characteristics and have been classified as "immun-
odeficiency associated lymphoproliferative disorders" in
the World Health Organization Classification [3]. Some
cases, particularly in the post-transplant setting and in
methotrexate-associated lymphoproliferative disorders,
show a premalignant disease state with an antigen-stimu-
lated polyclonal proliferation of lymphocytes (usually B-
cells). Distinction of this premalignant phase of disease is
important, particularly in immunosuppressed patients,
since modulation of the patients' drug regimen often
results in resolution of the disorder without the use of
chemotherapy.
Psoriasis induces a relative immune deficient state and it
is likely that the resulting loss of immune surveillance
results in an increased incidence of lymphoma in this
population [4,5]. This tendency may be exacerbated byDiagnostic Pathology 2008, 3:13 http://www.diagnosticpathology.org/content/3/1/13
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Lymph node biopsy Figure 1
Lymph node biopsy. Biopsy of the enlarged lymph node revealed an intact capsule and obliterated sinuses. A diffuse infiltrate 
effaced the normal nodal architecture (Upper left panel, hematoxylin and eosin, original magnification ×100). The infiltrate was 
composed of an admixture of small lymphocytes, macrophages, and plasma cells (Upper right panel, hematoxylin and eosin, 
original magnification ×400). The infiltrate was composed of a mixture of CD3 positive T-cells (including both CD4 and CD8 
positive cells) and CD20 positive B-cells. Numerous macrophages were also CD4 positive (Original magnification ×400).Diagnostic Pathology 2008, 3:13 http://www.diagnosticpathology.org/content/3/1/13
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the use of immunosuppressant and immunomodulatory
drugs such as methotrexate and the new biologic medica-
tions that further dysregulate the immune system.
Since the approval of TNFα inhibitors, there have been
several reports of non-Hodgkin lymphoma arising in this
background. The largest series included 18 patients
treated with etanercept [6]. Notably, two of these individ-
uals had a history of psoriatic arthritis; their specific char-
acteristics could not be extracted from the other cases due
to the presentation of clinical information. Besides the
above study of Brown et al, there is currently minimal
other data regarding the risk of lymphoma in psoriatic
patients. Adams et al reported a fatal aggressive cutaneous
T-cell lymphoma developing 18 months after initiation of
etanercept for psoriatic arthritis [7]. Although less fre-
quent, Hodgkin's and non-Hodgkin's lymphoma have
also been reported in patients treated with efalizumab [8].
However, some lymphoid proliferations occurring in
patients treated with biologics may be successfully treated
without the use of antineoplastic regimens. T cell develop-
ment and recruitment are facilitated by numerous
cytokines including TNFα, which acts as a potent media-
tor of cell death in cells expressing its receptor [9]. In this
capacity TNFα has important functions in inflammation
and host antitumoral responses. TNFα also interacts with
a variety of other transiently expressed ligands such as
CD30 and CD95 (FAS), which are expressed on numerous
cell types including activated T cells [9]. Thus, blocking
TNFα would be expected to result in a dysregulation of
these highly choreographed interactions, resulting in a
non-malignant expansion of cells expressing TNF ligands,
including activated T cells. Furthermore, when coupled
with an anti-CD11a antibody these activated T-cells are
excluded from the skin resulting in compartmentalization
in the blood and likely lymph nodes. In fact, treatment
with efalizumab results in a mean increase of white blood
cell count, a doubling of mean lymphocyte counts and an
increase in eosinophils counts due to decreased leukocyte
adhesion to blood vessel walls and decreased trafficking
from the vascular compartment to tissues. We postulate
Lymph node biopsy Figure 2
Lymph node biopsy. Follicular destruction was demonstrated with immunohistochemistry, which revealed small clusters of 
CD10 positive small lymphocytes, corresponding to the residual germinal centers (Upper right panel, original magnification 
×400). CD23 immunohistochemistry showed the dendritic cell network to be essentially obliterated (Lower right panel, origi-
nal magnification ×400). For comparison, normal germinal centers stained for CD10 and CD23 are illustrated in the upper left 
and lower left panels, respectively (Original magnification ×400).Publish with BioMed Central    and   every 
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that these mechanisms are responsible for this patient's
lymphoid proliferation. Therefore, during transition peri-
ods when overlapping these biologic therapies, clinicians
should be aware of the potentiating side effects, which
could result in transient lymphadenopathy simulating a
malignant lymphoproliferative disorder.
Acknowledgements
Written informed consent was obtained from the patient for publication of 
this Case report and accompanying images. A copy of the written consent 
is available for review by the Editor-in-Chief of this journal.
References
1. Krueger G, Callis K: Potential of tumor necrosis factor inhibi-
tors in psoriasis and psoriatic arthritis.  Arch Dermatol 2004,
140(2):218-225.
2. Scheinfeld N: A comprehensive review and evaluation of the
side effects of the tumor necrosis factor alpha blockers
etanercept, infliximab and adalimumab.  J Dermatolog Treat
2004, 15(5):280-294.
3. Jaffe ES, Harris NL, Stein H, Vardiman JW: World Health Organi-
zation Classification of Tumors. Pathology and Genetics of
Tumors of Haematopoietic and Lymphoid Tissues.  Lyon ,
IARC Press; 2001. 
4. Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J:
Psoriasis, its treatment, and cancer in a cohort of Finnish
patients.  J Invest Dermatol 2000, 114(3):587-590.
5. Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL:
The risk of malignancy associated with psoriasis.  Arch Derma-
tol 2001, 137(6):778-783.
6. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM:
Tumor necrosis factor antagonist therapy and lymphoma
development: twenty-six cases reported to the Food and
Drug Administration.  Arthritis Rheum 2002, 46(12):3151-3158.
7. Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, Kup-
per TS: Aggressive cutaneous T-cell lymphomas after TNFal-
pha blockade.  J Am Acad Dermatol 2004, 51(4):660-662.
8. Berthelot C, Cather J, Jones D, Duvic M: Atypical CD8+ cutane-
ous T-cell lymphoma after immunomodulatory therapy.  Clin
Lymphoma Myeloma 2006, 6(4):329-332.
9. Schattner EJ, Casali P: The immune system: structure and func-
tion.  In Neoplastic hematopathology Second edition edition. Edited by:
Knowles DM. Philadelphia , Lippincott Williams and Wilkins;
2001:80-82. 